Nilotinib Zentiva

Nilotinib, the active ingredient in Nilotinib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is used to treat chronic myeloid leukemia in its chronic, accelerated, or blast phases.

GNH USA supplies Nilotinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for bulk and parcel shipments across EU, Asia, Africa and the Americas. All products are manufactured under GMP‑certified facilities and undergo rigorous release testing before distribution.

Nilotinib acts on the BCR‑ABL tyrosine kinase pathway and is employed in the management of chronic myeloid leukemia. - Chronic phase CML: reduces leukemic cell proliferation and achieves hematologic remission. - Accelerated phase CML: helps attain cytogenetic response and disease control. - Blast phase CML: contributes to disease stabilization when combined with other therapies. - Imatinib‑resistant CML: provides an alternative targeted therapy for patients with prior TKI failure.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Elevated liver enzymes: mild to moderate increase in ALT or AST. - Nausea: occasional gastrointestinal discomfort. - Diarrhea: watery stools, often self‑limiting. - Rash: mild skin eruptions.

Serious or Rare Side Effects: - Cardiac QT prolongation: risk of arrhythmia requiring ECG monitoring. - Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain. - Severe hepatotoxicity: marked elevation of liver enzymes or jaundice.

When prescribing Nilotinib, clinicians should consider several precautionary measures to ensure patient safety. - Baseline ECG: assess QT interval before initiating therapy. - Electrolyte monitoring: correct hypokalemia, hypomagnesemia, and hypocalcemia to reduce cardiac risk. - Hepatic function: evaluate liver enzymes regularly during treatment. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Nilotinib interacts with several medicines, necessitating careful review of a patient’s medication regimen.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase nilotinib exposure. - QT‑prolonging agents (e.g., amiodarone, sotalol): may exacerbate cardiac risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce nilotinib absorption; separate dosing by at least 2 hours. - St. John’s wort: induces CYP3A4 and may lower nilotinib levels. - Warfarin: may require INR monitoring due to potential metabolic interaction.